JD-5037

TargetMol
Product Code: TAR-T4453
Supplier: TargetMol
CodeSizePrice
TAR-T4453-1mg1mg£100.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-2mg2mg£113.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-5mg5mg£140.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-1mL1 mL * 10 mM (in DMSO)£157.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-10mg10mg£185.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-25mg25mg£279.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-50mg50mg£383.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T4453-100mg100mg£536.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
CAS:
1392116-14-1
Formula:
C27H27Cl2N5O3S
Molecular Weight:
572.51
Pathway:
GPCR/G Protein
Purity:
0.9887
SMILES:
CC(C)[C@H](N=C(NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](C(=N1)c1ccc(Cl)cc1)c1ccccc1)C(N)=O
Target:
Cannabinoid Receptor

References

Tan S, Liu H, Ke B, et al. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/??arrestin1/Akt pathway[J]. British Journal of Pharmacology. 2020, 177(12): 2830-2847. Chorvat RJ.etal.Peripherally restricted CB1 receptor blockers.Bioorg Med Chem Lett. 2013 Sep 1;23(17):4751-60. Mukhopadhyay B,etal.Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.Hepatology. 2015 May;61(5):1615-26. Tan S, Liu H, Ke B, et al. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/??arrestin1/ Akt pathway. The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/??arrestin1/Akt pathway. British Journal of Pharmacology. 2020, 177(12): 2830-2847 Knani I,etal.Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome.Mol Metab. 2016 Oct 22;5(12):1187-1199. Li P, Lin Q, Sun S, et al. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism. Cell Death & Disease. 2022, 13(9): 1-15.